Molecular and cellular pathophysiology of preclinical Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Although the two pathological hallmarks of Alzheimer's disease (AD), senile plaques composed of amyloid-β (Aβ) peptides and neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau, have been studied extensively in postmortem AD and relevant animal and cellular models, the pathogenesis of AD remains unknown, particularly in the early stages of the disease where therapies presumably would be most effective. We and others have demonstrated that Aβ plaques and NFTs are present in varying degrees before the onset and throughout the progression of dementia. In this regard, aged people with no cognitive impairment (NCI), mild cognitive impairment (MCI, a presumed prodromal AD transitional state), and AD all present at autopsy with varying levels of pathological hallmarks. Cognitive decline, a requisite for the clinical diagnosis of dementia associated with AD, generally correlates better with NFTs than Aβ plaques. However, correlations are even higher between cognitive decline and synaptic loss. In this review, we illustrate relevant clinical pathological research in preclinical AD and throughout the progression of dementia in several areas including Aβ and tau pathobiology, single population expression profiling of vulnerable hippocampal and basal forebrain neurons, neuron plasticity, neuroimaging, cerebrospinal fluid (CSF) biomarker studies and their correlation with antemortem cognitive endpoints. In each of these areas, we provide evidence for the importance of studying the pathological hallmarks of AD not in isolation, but rather in conjunction with other molecular, cellular, and imaging markers to provide a more systematic and comprehensive assessment of the multiple changes that occur during the transition from NCI to MCI to frank AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“In contrast to the original “amyloid cascade” hypothesis that Aβ plaques drive the neuropathological cascade leading to dementia [11], Dr.”
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Identification of Novel Genes Coding for Small Expressed RNAs
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001) · Science · doi:10.1126/science.1064921 · Cited by 4,956
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 1×
“These observations indicate that there may be no clear demarcation of neuropathology between some NCI, MCI and AD brains using the Thal staging criteria for amyloid [37] or the Braak staging criteria for NFTs”
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 1×
“Another possibility is that synaptic protein loss is associated with an increase in soluble Aβ1-42 (sAβ1-42), which has been shown to increase during the progression of AD and is closely associated with changes in cognition [57].”
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885 · cited 1×
“The increase in oxidative stress in aMCI was expected since numerous previous studies have emphasized such a scenario in the progression of the disease [53-56] Unexpected was that oxidative stress increased in the HPNCI cohort, further supporting the idea that this”
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1×
“Another example of early neural reorganization is associated with entorhinal layer II glutamatergic neurons that innervate the hippocampus and degenerate early in the disease process [78].”
A brain-specific microRNA regulates dendritic spine development
Schratt, G. M., Tuebing, F., Nigh, E. A., Kane, C. G., Sabatini, M. E., Kiebler, M., & Greenberg, M. E. (2006) · Nature · doi:10.1038/nature04367 · Cited by 1,786
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · cited 1×
“An investigation of a small number of NCI subjects from the Rush Religious Orders Study (RROS) cohort revealed relatively similar percentages of low (40%) and high (60%) Braak scores compared to NCI, MCI and AD subjects examined [42] demonstrated a minor association between episodic memory and neuropathology using NIA…”
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185 · cited 1×
“17 control and non-AD dementias and demonstrated topographical patterns similar to neuropathological stages, suggesting their utility for assessing tau-related neuronal injury in vivo [150, 156, 157].”
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183 · cited 1×
“AD brains display altered expression of miRNAs that regulate BACE1 enzyme [105, 106] and are linked to tau phosphorylation [107-109] and proinflammatory actions [107, 110-112].”
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 1×
“It binds most prominently in NPs and vascular Aβ associated with cerebral amyloid angiopathy (CAA) [131], but does not bind to classic intracellular NFTs or other neuropathological elements [132].”
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 1×
“Findings indicate that loss of hippocampal volume and the ratio of CSF Aβ42 to total tau or phospho-tau are predictive of longitudinal changes in cognitive measures [121-124].”
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“Interestingly, dimeric Aβ induces tau phosphorylation and dystrophic axonal profiles [62], suggesting a prion-like seeding or propagation mechanism underlying AD pathogenesis [63] or that selectively vulnerable subcortical long projection neurons may be sensitive to retrograde toxicity of Aβ oligomers.”
Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease
Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630428100 · Cited by 831
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768 · cited 1×
“However, during the last few years this hypothesis has been challenged by clinical pathological investigations demonstrating a large population of older individuals that display extensive pathological hallmarks of this disease, amyloid and tau lesions but do not develop dementia even in the eighth and ninth decades of…”
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686 · cited 2×
“The MTL memory circuit is highly neuroplastic [68] [69] and behaviorally resistant [22] to AD pathology.”
Self-citationBuchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 2×
“AV-1451 also has a promising pattern of retention in relation to clinical severity of AD [163], with greater PET retention in MCI and AD patients compared to NCI [154].”
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643 · cited 2×
“Neuropathological reports show that AD pathology is limited within the precuneus suggesting a disconnection between amyloid toxicity and histopathology in this brain region [89] [88].”
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615
Oxidative stress in the progression of Alzheimer disease in the frontal cortex
Ansari, M. A., & Scheff, S. W. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181cb5af4 · Cited by 605 · cited 1×
“The increase in oxidative stress in aMCI was expected since numerous previous studies have emphasized such a scenario in the progression of the disease [53-56] Unexpected was that oxidative stress increased in the HPNCI cohort, further supporting the idea that this”
Self-citation[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections
Braak, H., & Braak, E. (1991) · Brain Pathology · doi:10.1111/j.1750-3639.1991.tb00661.x · Cited by 598 · cited 3×
“Later stages feature neuritic and dense cored Aβ plaques [32].”
Evidence of increased oxidative damage in subjects with mild cognitive impairment
Keller, J. N., Schmitt, F. A., Scheff, S. W., Ding, Q., Chen, Q., Butterfield, D. A., & Markesbery, W. R. (2005) · Neurology · doi:10.1212/01.wnl.0000156156.13641.ba · Cited by 539
Self-citationMild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions
Bennett, D. A., Schneider, J. A., Bienias, J. L., Evans, D. A., & Wilson, R. S. (2005) · Neurology · doi:10.1212/01.wnl.0000152982.47274.9e · Cited by 537
Longitudinal Modeling of Age-Related Memory Decline and the APOE ε4 Effect
Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., Baxter, L. C., Rapcsak, S. Z., Shi, J., Woodruff, B. K., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809437 · Cited by 528
Identifying and validating biomarkers for Alzheimer's disease
Humpel, C. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.09.007 · Cited by 484 · cited 1×
“However, the inherent variability of AD neuropathology in the aged NCI, MCI and AD brain is also reflected by variation in these markers, particularly CSF and blood amyloid and tau [175], resulting in equivocal specificity and sensitivity for identifying at-risk individuals.”
Age-specific incidence rates of Alzheimer’s disease: The Baltimore Longitudinal Study of Aging
Kawas, C., Gray, S., Brookmeyer, R., Fozard, J., & Zonderman, A. (2000) · Neurology · doi:10.1212/wnl.54.11.2072 · Cited by 472
Neuropathologic Substrate of Mild Cognitive Impairment
Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., & Wekstein, D. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.38 · Cited by 460 · cited 1×
“Neuropathological examinations of older people who died with a clinical diagnosis of NCI or MCI often reveal similar pathological signatures to those with frank AD [40, 89, 115-118].”
Alterations of the microRNA network cause neurodegenerative disease
Hébert, S. S., & De Strooper, B. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.003 · Cited by 452 · cited 2×
“The presence of small non-coding microRNAs (miRNAs) that negatively regulate mRNA stability [98] is an under researched area in AD [99, 100].”
Neuroplasticity Failure in Alzheimer's Disease
Mesulam, M.-M. (1999) · Neuron · doi:10.1016/s0896-6273(00)81109-5 · Cited by 449 · cited 2×
“In 1999, Mesulam [14] wrote, “It seems as if the Aβ plaques appear at the wrong time and in the wrong places with respect to the clinical dementia and there is little evidence that they cause the NFT”.”
Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425
Rajasethupathy, P., Fiumara, F., Sheridan, R., Betel, D., Puthanveettil, S. V., Russo, J. J., Sander, C., Tuschl, T., & Kandel, E. (2009) · Neuron · doi:10.1016/j.neuron.2009.05.029 · Cited by 406
Structural Correlates of Cognition in Dementia: Quantification and Assessment of Synapse Change
DeKosky, S. T., Scheff, S. W., & Styren, S. D. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0056 · Cited by 405
Self-citationDissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387
Cataldo, A. M., Petanceska, S., Terio, N. B., Peterhoff, C. M., Durham, R., Mercken, M., Mehta, P. D., Buxbaum, J., Haroutunian, V., & Nixon, R. A. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.027 · Cited by 363
Neurodegenerative Diseases: Expanding the Prion Concept
Walker, L. C., & Jucker, M. (2015) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071714-033828 · Cited by 361 · cited 1×
“Interestingly, dimeric Aβ induces tau phosphorylation and dystrophic axonal profiles [62], suggesting a prion-like seeding or propagation mechanism underlying AD pathogenesis [63] or that selectively vulnerable subcortical long projection neurons may be sensitive to retrograde toxicity of Aβ oligomers.”
Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353
Sex differences in Alzheimer's disease and other dementias
Mazure, C. M., & Swendsen, J. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00067-3 · Cited by 350
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease
Banzhaf‐Strathmann, J., Benito, E., May, S., Arzberger, T., Tahirovic, S., Kretzschmar, H., Fischer, A., & Edbauer, D. (2014) · The EMBO Journal · doi:10.15252/embj.201387576 · Cited by 347 · cited 1×
“AD brains display altered expression of miRNAs that regulate BACE1 enzyme [105, 106] and are linked to tau phosphorylation [107-109] and proinflammatory actions [107, 110-112].”
Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4144 · Cited by 332 · cited 1×
“The relatively short radioactive half-life of carbon-11 (~20 minutes), limits the distribution of PiB to PET imaging centers and supports the requirement of longer lived radioligands such as F18 flutemetamol a 3’-fluoro analog of PiB (3’-F-PiB) [141], F-18 florbetapir [142] and F-18 florbetaben [143].”
Absalon, S., Kochanek, D. M., Raghavan, V., & Krichevsky, A. M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1327-13.2013 · Cited by 302
Nelson, P. T., Jicha, G. A., Schmitt, F. A., Liu, H., Davis, D. G., Mendiondo, M. S., Abner, E. L., & Markesbery, W. R. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31815c5efb · Cited by 292 · cited 1×
“A review of the literature suggests that cognition is affected by NPs and not diffuse plaques (DPs) [48] [49].”
Preclinical Alzheimer disease—the challenges ahead
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291
Haroutunian, V. (1998) · Archives of Neurology · doi:10.1001/archneur.55.9.1185 · Cited by 289
Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · cited 1×
“A strong concordance between PiB PET and CSF Aβ1-42 exists in NCI [168], and mixed cohorts of NCI and AD [169] [170], with no correlation between PiB PET and CSF tau [171].”
Cui, J. G., Li, Y. Y., Zhao, Y., Bhattacharjee, S., & Lukiw, W. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178848 · Cited by 274 · cited 1×
“AD brains display altered expression of miRNAs that regulate BACE1 enzyme [105, 106] and are linked to tau phosphorylation [107-109] and proinflammatory actions [107, 110-112].”
Neuropathologic Alterations in Mild Cognitive Impairment: A Review
Markesbery, W. R. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1220 · Cited by 236 · cited 2×
“3) as well as NFT pathology equal to or greater than what is often seen neuropathologically in mild to moderate AD, challenging the singular notion that these lesions alone drive dementia onset [21] [22] [23].”
Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease
Praticò, D., & Sung, S. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6209 · Cited by 229 · cited 1×
“The increase in oxidative stress in aMCI was expected since numerous previous studies have emphasized such a scenario in the progression of the disease [53-56] Unexpected was that oxidative stress increased in the HPNCI cohort, further supporting the idea that this”
Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease
Leung, R., Proitsi, P., Simmons, A., Lunnon, K., Güntert, A., Kronenberg, D., Pritchard, M., Tsolaki, M., Mecocci, P., Kloszewska, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064971 · Cited by 160 · cited 1×
“Panels of plasma inflammatory marker and related proteins [165], either alone or in combination with CSF biomarkers, have been proposed.”
Vana, L., Kanaan, N. M., Ugwu, I. C., Wuu, J., Mufson, E. J., & Binder, L. I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.044 · Cited by 138 · cited 1×
“Pretangle-bearing CBF neurons (marked with the tau antibody pS422) [95] displayed a significant upregulation rab5, rab7, Ctsd, and Lamp1 expression.”
Self-citationBancher, C., Jellinger, K., Lassmann, H., Fischer, P., & Leblhuber, F. (1996) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02189115 · Cited by 130
Clinical validity of Braak neuropathological staging in the oldest-old
Gold, G., Bouras, C., Kövari, E., Canuto, A., González Glaría, B., Malky, A., Hof, P. R., Michel, J.-P., & Giannakopoulos, P. (2000) · Acta Neuropathologica · doi:10.1007/s004010051163 · Cited by 128
Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer’s disease
Arnold, S. E., Louneva, N., Cao, K., Wang, L.-S., Han, L.-Y., Wolk, D. A., Negash, S., Leurgans, S. E., Schneider, J. A., Buchman, A. S., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.004 · Cited by 123
APOE is a major susceptibility gene for Alzheimer’s disease
Roses, A. D., & Saunders, A. M. (1994) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(94)90091-4 · Cited by 108 · cited 1×
“The genetic risk factor for AD, ApoE ε4, may also play a prominent role in the development of cognitive decline and pathology in AD [82].”
Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons
Riudavets, M. A., Iacono, D., Resnick, S. M., O’Brien, R., Zonderman, A. B., Martin, L. J., Rudow, G., Pletnikova, O., & Troncoso, J. C. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.005 · Cited by 106 · cited 1×
“Clinical pathological investigations also indicate preserved number and larger neuronal size in the hippocampus in “asymptomatic AD” compared with normal, MCI and clinical AD [74] indicating early reorganizational responses.”
Scheff, S. W., Ansari, M. A., & Mufson, E. J. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.030 · Cited by 100
Self-citationIn vivo assessment of amyloid‐β deposition in nondemented very elderly subjects
Mathis, C. A., Kuller, L. H., Klunk, W. E., Snitz, B. E., Price, J. C., Weissfeld, L. A., Rosario, B. L., Lopresti, B. J., Saxton, J. A., Aizenstein, H. J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23797 · Cited by 98 · cited 1×
“Interestingly, 10%-20% of AD patients are PiB(-), in agreement with autopsy reports [136] [40], and 20-30% of NCI are also PiB(+)[137] , which increases up to 65% in those >80 years [40, 138], suggesting a clinical misdiagnosis and/or a distinct dementia syndrome.”
Neuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly
Malek-Ahmadi, M., Perez, S. E., Chen, K., & Mufson, E. J. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160365 · Cited by 73
Self-citationPreclinical AD Workgroup staging: Pathological correlates and potential challenges
Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71
Cited by
Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease
Kelly, S. C., He, B., Perez, S. E., Ginsberg, S. D., Mufson, E. J., & Counts, S. E. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0411-2 · Cited by 286
“postsynaptic gene expression in vulnerable LC neurons may signal perturbations prior to the onset of aMCI that are indicative of a failure in neuroplastic and/or remodeling programs [38, 39, 68, 89].”
Self-citationKapogiannis, D., Mustapic, M., Shardell, M. D., Berkowitz, S. T., Diehl, T. C., Spangler, R. D., Tran, J., Lazaropoulos, M. P., Chawla, S., Gulyani, S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2462 · Cited by 241
Aghourian, M., Legault-Denis, C., Soucy, J.-P., Rosa-Neto, P., Gauthier, S., Kostikov, A., Gravel, P., & Bédard, M.-A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.183 · Cited by 220
Sharoar, M. G., Palko, S., Ge, Y., Saido, T. C., & Yan, R. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00464-1 · Cited by 78
“Specifically, the toxic form of oligomeric Aβ during the pre-clinical phase induces local toxicity that advances both intraand extra-neuronal pathologies such as neurofibrillary tangles, dystrophic neurites (DNs), mitochondrial degeneration, and glial dysfunction [3, 6, 7].”
BackgroundLiu, Y., Zhang, Y., Liu, P., Bai, H., Li, X., Xiao, J., Yuan, Q., Geng, S., Yin, H., Zhang, H., et al. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.11.004 · Cited by 45
Retracted
Metadata
- Authors
- Mufson, E. J., Ikonomovic, M. D., Counts, S. E., Perez, S. E., Malek-Ahmadi, M., Scheff, S. W., & Ginsberg, S. D.
- Venue
- Behavioural Brain Research
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 311
- Pages
- 54-69
- ISSN
- 0166-4328 (ISSN-L)
- OpenAlex
- W2356948138
- Cited by
- 127
- References
- 78
- FWCI
- 12.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.